BACKGROUND: Effector CD4+ helper T cells have historically been classified into T helper 1 (Th1) and Th2 based on the production of signature cytokines. The recently identified interleukin (IL)-17 cytokine family plays important roles in host immunity against intracellular pathogens and in chronic inflammatory conditions; data have implicated IL-17 in autoimmune and viral liver disease. METHODS: This study used three patient groups with HCV infection: acute HCV who either cleared spontaneously or became chronically infected (n = 12), endstage liver disease from whom both peripheral and intrahepatic lymphocytes were studied directly ex vivo (n = 11), and 134 patients with different stages of HCV-related fibrosis from whom serum was collected concurrently with liver biopsy. Normal healthy subjects (n = 41) served as controls. RESULTS: Acute HCV was not associated with expansion of either CD4+ or CD8+ T cells producing IL-17 (Th17, Tc17) or IL-22, and frequencies did not differ in the blood of patients who cleared versus became persistently infected. The hepatic compartment of chronic HCV patients demonstrated statistically more CD4+ and CD8+ that produced IL-17, IL-22 or both as compared to peripheral blood. These T cells displayed a distinct phenotypic profile, high expression of the homing receptor CD161 and low levels of inhibitory receptors, mucin-domain-containing-molecule-3 (Tim-3) and programmed-death 1. Using a sensitive ELISA, we found no significant differences in serum levels of IL-17 according to HCV-related fibrosis. CONCLUSIONS: In chronic HCV, T cells producing IL-17/IL-22 may home to the liver; however, circulating levels of IL-17 do not correlate with fibrosis.
BACKGROUND: Effector CD4+ helper T cells have historically been classified into T helper 1 (Th1) and Th2 based on the production of signature cytokines. The recently identified interleukin (IL)-17 cytokine family plays important roles in host immunity against intracellular pathogens and in chronic inflammatory conditions; data have implicated IL-17 in autoimmune and viral liver disease. METHODS: This study used three patient groups with HCV infection: acute HCV who either cleared spontaneously or became chronically infected (n = 12), endstage liver disease from whom both peripheral and intrahepatic lymphocytes were studied directly ex vivo (n = 11), and 134 patients with different stages of HCV-related fibrosis from whom serum was collected concurrently with liver biopsy. Normal healthy subjects (n = 41) served as controls. RESULTS: Acute HCV was not associated with expansion of either CD4+ or CD8+ T cells producing IL-17 (Th17, Tc17) or IL-22, and frequencies did not differ in the blood of patients who cleared versus became persistently infected. The hepatic compartment of chronic HCV patients demonstrated statistically more CD4+ and CD8+ that produced IL-17, IL-22 or both as compared to peripheral blood. These T cells displayed a distinct phenotypic profile, high expression of the homing receptor CD161 and low levels of inhibitory receptors, mucin-domain-containing-molecule-3 (Tim-3) and programmed-death 1. Using a sensitive ELISA, we found no significant differences in serum levels of IL-17 according to HCV-related fibrosis. CONCLUSIONS: In chronic HCV, T cells producing IL-17/IL-22 may home to the liver; however, circulating levels of IL-17 do not correlate with fibrosis.
Authors: Eva Billerbeck; Yu-Hoi Kang; Lucy Walker; Helen Lockstone; Stefanie Grafmueller; Vicki Fleming; Jonathan Flint; Chris B Willberg; Bertram Bengsch; Bianca Seigel; Narayan Ramamurthy; Nicole Zitzmann; Eleanor J Barnes; Jonarthan Thevanayagam; Anisha Bhagwanani; Alasdair Leslie; Ye H Oo; Simon Kollnberger; Paul Bowness; Oliver Drognitz; David H Adams; Hubert E Blum; Robert Thimme; Paul Klenerman Journal: Proc Natl Acad Sci U S A Date: 2010-01-28 Impact factor: 11.205
Authors: Chia C Wang; Elizabeth Krantz; Jared Klarquist; Meighan Krows; Lanamarie McBride; Edward P Scott; Thomas Shaw-Stiffel; Scott J Weston; Hanne Thiede; Anna Wald; Hugo R Rosen Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento Journal: Immunology Date: 2017-03-13 Impact factor: 7.397
Authors: Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller Journal: J Gastroenterol Hepatol Date: 2019-02-25 Impact factor: 4.029
Authors: Timothy T Spear; Yuan Wang; Thomas W Smith; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura Journal: Mol Ther Date: 2018-02-02 Impact factor: 11.454
Authors: Derek A Pociask; Erich V Scheller; Sivanarayana Mandalapu; Kevin J McHugh; Richard I Enelow; Cheryl L Fattman; Jay K Kolls; John F Alcorn Journal: Am J Pathol Date: 2013-03-11 Impact factor: 4.307
Authors: Hai-Chon Lee; Sung-Sang J Sung; Peter D Krueger; Yoon-Ah Jo; Hugo R Rosen; Steven F Ziegler; Young S Hahn Journal: Hepatology Date: 2013-03-14 Impact factor: 17.425